Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1

Abstract

The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. The compounds of formula (I) are useful as PARP-1 inhibitors for the treatment of, e.g. cancer.

Description

technical field [0001] The present invention relates to new compounds of general formula (I), their stereoisomers, regioisomers (positional isomers, regioisomers), tautomeric forms and new intermediates involved in their synthesis, and their pharmaceutically acceptable salts , Pharmaceutical solvates and pharmaceutical compositions containing them. The present invention also relates to the preparation of novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and Methods of novel intermediates involved in their synthesis. [0002] [0003] The invention further relates to compounds which result in the selective inhibition of poly(ADP-ribose) polymerase-1. Background technique [0004] Exploiting synthetic lethal relationships is a trusted therapeutic strategy to target genetic differences between tumor and...

AI Technical Summary

Problems solved by technology

[0069] Although several compounds have been reported in the literature as PARP-I inhibitors, few have actually demonstrated actual clinical benefit and none have been approved to date

Images